(Q28248916)

https://api.crossref.org/works/10.2146%2FAJHP080248

Epidemiology and outcomes of osteoporotic fractures

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Osteoporosis management in a Medicaid population after the Women's Health Initiative study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Transmission of human herpesvirus 8 by blood transfusion

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Current approaches to the management of osteoporosis in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

The management of osteoporosis following hip fracture: Have we improved our care?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Osteoporosis intervention following distal forearm fractures: a missed opportunity?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Osteoporosis follow-up after wrist fractures following minor trauma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Assessment of compliance with osteoporosis treatment and its consequences in a managed care population

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Compliance with drug therapies for the treatment and prevention of osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Determinants of adherence to osteoporosis treatment in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Underuse of osteoporosis medications in elderly patients with fractures

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Initiation of osteoporosis treatment after bone mineral density testing

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Bone density and fracture risk in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Sex-specific and race-specific hip fracture rates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Racial variations in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Osteoporosis preventive care in white and black women in community family medicine settings.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Differences in outcome between black and white elderly hip fracture patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Race and sex differences in mortality following fracture of the hip

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: Osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Osteoporosis screening and education in community pharmacies using a team approach

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248

Pharmacist-provided quantitative heel ultrasound screening for rural women at risk of osteoporosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080248